| INTRODUC TI ON
Allergic rhinitis (AR) is a type I allergic disease characterized by repetitive sneezing, watery rhinorrhea, pruritus, and nasal blockage.
One common causative antigen is the house dust mite (HDM), for example, Dermatophagoides pteronyssinus and Dermatophagoides farinae species.
1 Allergenic reactions in HDM allergy are related to the adaptive immune response, which depends on immunoglobulin E (IgE), 1 and allergen immunotherapy involves administration of a specific allergen to provide protection against allergic symptoms and inflammatory reactions in patients with IgE-mediated allergy.
1
A sublingual tablet containing standardized allergen extracts from D. pteronyssinus and D. farinae in a total allergenic activity ratio (expressed as index of reactivity [IR]) of 1:1 has been developed. 2, 3 Research has shown that the 300IR HDM tablet is effective and well tolerated in adult and adolescent patients aged 12 years and older with AR. In two double-blind, placebo-controlled studies in adults and adolescents with HDM-associated AR, 300IR HDM tablets significantly reduced mean average adjusted symptom scores (AASS) compared with placebo. 2, 3 Although local allergic reactions occurred more frequently with active treatment than with placebo, the favorable safety profile of 300IR HDM tablets was confirmed. 2, 3 In addition, the effectiveness of one year of treatment with 300IR HDM tablets was maintained for a subsequent year after ceasing treatment. 2 In Japan, HDM tablets were approved in March 2015 for "allergen immunotherapy for AR due to house dust mites" in adults and adolescents ≥12 years of age (Actair ® Sublingual Tablets 100 Units According to a survey in 2002, the prevalence of AR in elementary students across 11 prefectures in western Japan was 20.5%. 5 Because of the common underlying cellular processes, AR in children is a risk factor for subsequent development of allergic airways diseases, including asthma. 6 Allergen immunotherapy provides protection against allergic symptoms that is not limited to AR 7 and may prevent additional allergies and asthma from developing. 6 Therefore, it is important to start allergen immunotherapy for AR in young children. 6 However, the efficacy, safety, and immunological response of HDM tablets in pediatric patients have not yet been demonstrated.
The aim of this double-blind, randomized, placebo-controlled study was to assess the efficacy, safety, and immunological response of standardized HDM allergen extract tablets in pediatric (≥5 and ≤16 years old) patients with perennial AR. 
| ME THODS

| Study design and treatment protocol
The study comprised a screening period (up to 24 weeks before enrollment), a 2-week pretreatment observation period, a 52-week treatment period, and a 1-week post-treatment observation period.
After the pretreatment observation period, patients were randomized (web-based system) 1:1 to receive placebo or HDM tablets (active) once daily by a statistical minimization method using the al- 
| Study population
The main inclusion criteria were as follows: male and female outpa- 
| End-points
The primary efficacy end-point was the AASS, defined as the av- and general improvement as assessed by investigators. 1, 3, 7, 8 Definitions of the efficacy scores are shown in the footnotes to Table 2 . Investigators evaluated general improvement as marked worsening, slight to moderate worsening, no change, slight to moderate improvement, or marked improvement compared with baseline. Adherence was assessed by the investigator based on study drug tablets retrieved from patients or guardians.
At baseline and at Week 52 or discontinuation, mite antigen-specific IgE/IgG4 antibodies were analyzed at BML Inc, Kawagoe, Japan.
Safety was assessed by the reporting of adverse events (AEs) and serious AEs (SAEs), coded using the Medical Dictionary for Regulatory Activities, version 18.0.
| Statistical analysis
A target sample size of 400 patients was set to provide 168 patients per group (15% withdrawal rate) and 90% power to detect a difference in means of −0.96 between groups, assuming a common SD of 2.7, using a Student's t test. The safety analysis population included all patients who received at least one dose of study treatment and were GCP-compliant. The efficacy analysis population (full analysis set) included all patients in the safety analysis population who were assessed for efficacy. Baseline was defined as the pretreatment observation period.
The primary efficacy analysis used a mixed-effects model for • Adverse event (n = 2) 300IR HDM tablet (Full analysis set) n = 205 Placebo (Full analysis set) n = 217
Excluded (n = 14)
• Unassessed (n =14 )
Assessed for eligibility N = 484
Excluded (n = 46)
• Did not meet any of the inclusion criteria (n = 6)
• Met any of the exclusion criteria (n = 7)
• Others (n = 33)
| Patient disposition and baseline characteristics
Of the 438 randomized patients, 422 (96%; 205 active, 217 placebo)
were included in the full analysis set, and 403 (92%; 193 active, 210 placebo) completed the study (Figure 1 ). Only 8% of patients discontinued, mainly because of an AE.
The demographics and baseline characteristics for the history and severity of allergic airway disease were similar between the active and placebo groups ( Table 1 ). All patients were sensitized to D. pteronyssinus and D. farinae allergens based on IgE tests and had positive nasal provocation tests. Most patients in both groups had a treatment compliance rate of ≥80% (Table S1 ).
| Efficacy
The primary end-point, the AASS (LS mean) during the last 4 weeks of treatment (Weeks 48-52), was significantly lower in the active group compared with placebo (P = 0.0005; Figure 2A ). The LS mean difference (SE) in AASS between the active and placebo groups was (Table S2 ).
The ARTSS and ACS (LS means) were significantly lower in the active group compared with placebo during the last 4 weeks (Weeks 48-52). There was no significant difference in ARMS (LS mean) between the active and placebo groups. All nasal ISSs were consistently lower in the active group than in the placebo group, with significant differences ( Table 2 ).
The percentage of patients assessed by patients/guardians at Week 52 as "Improved" (sum of "Slight to moderate improvement"
and "Marked improvement") was significantly higher in the active group (78.8%) compared with placebo (58.3%, P < 0.0001), as was the percentage of patients with general improvement assessed by investigators (67.5% vs 57.4%, P = 0.0348; Figure 2B ).
| Immunological responses
The Week 52: baseline ratios of antigen-specific IgE and IgG4 were significantly greater in the active group than with placebo ( Figure 3 ; 
| Safety and tolerability
Almost all patients reported at least one AE during the study (Table 3 ).
The most common AEs (≥20% of patients) were nasopharyngitis, influenza, pharyngitis (both groups), and oral pruritus (active group only). baseline data are arithmetic mean Average Rhinitis Total Symptom Scores unadjusted for covariates. ***P value < 0.001, **P value < 0.01, *P value < 0.05 compared with placebo. HDM tablet, house dust mite allergen extract tablet. B, Overall assessment of treatment efficacy by patients or guardians and general improvement as assessed by investigators at Week 52. *P value < 0.05, ****P value < 0.0001, percentage of "improved" compared with placebo. HDM tablet, house dust mite allergen extract tablet.
streptococcal infection and viral infection that were resolved, and one patient with fracture that was resolving). Pseudocroup occurred on Day 22, 11 hours after study drug administration; the patient received oral betamethasone, inhaled adrenaline, and inhaled dexamethasone, and recovered on Day 23. The AE was severe, associated with cough and dyspnea, considered to be drug-related by the physician, and led to drug discontinuation. 
| D ISCUSS I ON
This definitive, large-scale study has demonstrated the efficacy and safety of sublingual tablets containing standardized allergen extracts of HDM in pediatric patients with perennial AR. In this 52-week, double-blind, randomized, placebo-controlled study, sublingual immunotherapy with HDM allergen extracts was associated with significant and sustained improvement in the symptoms of HDM-induced AR The immunological responses of HDM-specific IgE and IgG4 observed in previous studies were confirmed. 3 The safety profile of the HDM tablets in this pediatric population was consistent with that of adults, 2, 3 with no new safety concerns. These results indicate that HDM tablets are effective and well tolerated in pediatric patients with perennial AR, as in adults and adolescents. 2, 3 In this study, sublingual immunotherapy with HDM tablets was associated with significant and sustained (up to 1 year) improvement in symptoms of HDM-induced AR, compared with placebo. AASS was statistically significantly lower in the active group compared with placebo.
Improvements in AASS were observed in the first evaluation period (Weeks 8-10) and maintained thereafter, suggesting that the onset of action of HDM tablets occurs within the first 10 weeks of treatment.
In addition, the significant improvement in AASS was observed in TA B L E 2 Symptom and medication scores at Weeks 48-52 (full analysis set) Average combined score: the average of the daily Combined Scores, where the daily combined score = (RTSS/4 + RMS)/2. Individual Symptom Score: 0-4 for sneezing, rhinorrhea, nasal congestion, itchy eyes, and watery eyes, and 0-3 for nasal pruritus. HDM tablet, house dust mite allergen extract tablet; LS mean, leastsquares mean; N, number of patients; SE, standard error.
F I G U R E 3
House dust mite-specific serum immunoglobulins. Geometric means of the Week 52/baseline ratio are shown. ****P value < 0.0001 compared with placebo. IgE, immunoglobulin E; IgG4, immunoglobulin G4.
both younger (aged 5-11 years) and older (aged 12-16 years) patients.
Similarly, ARTSS, ACS, and all nasal ISSs were also significantly lower with the HDM tablets compared with placebo, consistent with previous studies. 2, 3 Although there was a tendency for ocular symptoms and ARMS to be improved with active treatment, there were no statistically significant between-group differences, most likely because ocular symptoms were mild at both baseline (data not shown) and at Weeks 48-52, and because very few patients in either group were treated with rescue medication. The relatively low level of ocular involvement at baseline is unsurprising given that nasal symptoms are predominant in HDM AR (as opposed to allergy to outdoor allergens, where ocular symptoms are more common). However, the relatively immature immune system in children, especially young children, should be considered when comparing immune responses to those of adults.
The safety profile of HDM tablets in Japanese pediatric patients was consistent with that of adults and adolescents. 2, 3 Although no new safety concerns were observed, the incidence rates of AEs in both treatment groups (96.8% in the active group and 94.5% in the placebo group) were higher than previously reported in adults and adolescents. 2, 3 This may be related to the long study duration and a higher incidence of infectious disease in pediatric patients compared with adults. Although almost all patients reported an AE during the study, most were mild to moderate and typically occurred during the first 2 weeks of treatment. Further, the incidence of treatment-related AEs in our pediatric population is similar to that reported in Japanese adult and adolescent populations.
3 Importantly, and similar to previous studies, there were no events of anaphylaxis that required adrenaline injection. 2, 3 However, as expected with any sublingual immunotherapy, 10, 11 severe allergic reactions affecting upper and lower airways, skin, conjunctiva, and multiple organ systems individually or in combination may be expected. Therefore, patients
and their guardians should be instructed on how to recognize the early signs and symptoms of these reactions. this immunotherapy should be an important part of AR therapy because nasal congestion, which is difficult to treat, was significantly improved.
In conclusion, sublingual immunotherapy with HDM tablets at a dose of 300IR was associated with significant and sustained improvement in symptoms of HDM-induced AR and had an acceptable safety and tolerability profile that was consistent with adults and adolescents. These results suggest that HDM tablets administered at 300IR once daily are an effective and well-tolerated option for pediatric patients with perennial AR
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